{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:18:55Z","timestamp":1784758735575,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.drudis.2019.03.022","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T19:19:59Z","timestamp":1553714399000},"page":"1644-1653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases"],"prefix":"10.1016","volume":"24","author":[{"given":"Alicia","family":"Arranz-Romera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Esteban-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garcia-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Arag\u00f3n-Navas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bravo-Osuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Herrero-Vanrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2019.03.022_bib0005","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.drudis.2019.03.022_bib0010","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/sj.eye.6701588","article-title":"Optic nerve and neuroprotection strategies","volume":"18","author":"Osborne","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2019.03.022_bib0015","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1093\/hmg\/ddx273","article-title":"Optic neuropathies: the tip of the neurodegeneration iceberg","volume":"26","author":"Carelli","year":"2017","journal-title":"Hum. Mol. Genet."},{"issue":"2018","key":"10.1016\/j.drudis.2019.03.022_bib0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.preteyeres.2018.02.002","article-title":"Neuroprotective strategies for retinal disease","volume":"65","author":"Pardue","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.drudis.2019.03.022_bib0025","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.exer.2010.08.009","article-title":"Neuroprotection in glaucoma \u2013 Is there a future role?","volume":"91","author":"Baltmr","year":"2010","journal-title":"Exp Eye. Res."},{"key":"10.1016\/j.drudis.2019.03.022_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11910-017-0733-2","article-title":"Neuroinflammation in neurodegenerative disorders\u2014a review","volume":"17","author":"Schain","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.drudis.2019.03.022_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2017.10.003","article-title":"Mitochondrial disorders of the retinal ganglion cells and the optic nerve","volume":"42","author":"Finsterer","year":"2018","journal-title":"Mitochondrion"},{"key":"10.1016\/j.drudis.2019.03.022_bib0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","article-title":"Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy","volume":"16","author":"Hussain","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drudis.2019.03.022_bib0045","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3940241","article-title":"Ischemic retinopathies: oxidative stress and inflammation","volume":"2017","author":"Rivera","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.drudis.2019.03.022_bib0050","article-title":"Inflammation in retinal vein occlusion","volume":"2013","author":"Deobhakta","year":"2013","journal-title":"Int. J. Inflam."},{"key":"10.1016\/j.drudis.2019.03.022_bib0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2014-305041","article-title":"Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel","volume":"99","author":"Gerding","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jddst.2017.07.001","article-title":"Novel technologies for the delivery of ocular therapeutics in glaucoma","volume":"42","author":"Andres-Guerrero","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0065","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/131970","article-title":"Safety and efficacy of adding fixed-combination brinzolamide\/timolol maleate to prostaglandin therapy for treatment of ocular hypertension or glaucoma","volume":"2015","author":"Hommer","year":"2015","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0070","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s12325-015-0246-9","article-title":"Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: a prospective multicenter open-label study","volume":"32","author":"Nakano","year":"2015","journal-title":"Adv. Ther."},{"key":"10.1016\/j.drudis.2019.03.022_bib0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/OPTH.S152507","article-title":"The 24-hour intraocular pressure control by tafluprost\/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma","volume":"12","author":"Nakamoto","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0080","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s10792-017-0601-8","article-title":"The efficacy and safety of bimatoprost\/timolol maleate, latanoprost\/timolol maleate, and travoprost\/timolol maleate fixed combinations on 24-h IOP","volume":"38","author":"Guven Yilmaz","year":"2018","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0085","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1517\/14656566.2013.813482","article-title":"Latanoprost\/timolol fixed combination for the treatment of glaucoma","volume":"14","author":"Konstas","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.drudis.2019.03.022_bib0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/0002512-200926020-00008","article-title":"Bimatoprost\/timolol: a review of its use in glaucoma and ocular hypertension","volume":"26","author":"Curran","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.drudis.2019.03.022_bib0095","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0161-6420(91)32173-0","article-title":"Additivity of prostaglandin F2\u03b1-1-isopropyl ester to timolol in glaucoma patients","volume":"98","author":"Lee","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2019.03.022_bib0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00002512-200320120-00008","article-title":"Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension","volume":"20","author":"Cvetkovic","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.drudis.2019.03.022_bib0105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bjophthalmol-2015-306778","article-title":"Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension","volume":"100","author":"Lewis","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0110","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.ophtha.2018.04.040","article-title":"Rho kinase inhibitors as a novel treatment for glaucoma and ocular hypertension","volume":"125","author":"Tanna","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2019.03.022_bib0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000459706","article-title":"Diabetic macular edema: emerging strategies and treatment algorithms","volume":"60","author":"Moisseiev","year":"2017","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0120","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2019.03.022_bib0125","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3928\/23258160-20170829-08","article-title":"Multicenter, randomized clinical trial to assess the effectiveness of intravitreal injections of bevacizumab, triamcinolone, or their combination in the treatment of diabetic macular edema","volume":"48","author":"Neto","year":"2017","journal-title":"Ophthal. Surg. Lasers Imaging Retin."},{"key":"10.1016\/j.drudis.2019.03.022_bib0130","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10792-016-0335-z","article-title":"Intravitreal diclofenac plus bevacizumab versus bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial","volume":"37","author":"Ghanbari","year":"2017","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10792-017-0496-4","article-title":"Intravitreal bevacizumab alone or combined with + mg triamcinolone in diabetic macular edema: a randomized clinical trial","volume":"38","author":"Riazi-Esfahani","year":"2018","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0140","unstructured":"Curcumin and intravitreal dexamethasone in diabetic macular edema (DIABEC). NCT03598205. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03598205?term5NCT03598205&rank51 [Accessed 20 February 2019]."},{"key":"10.1016\/j.drudis.2019.03.022_bib0145","first-page":"249","article-title":"Curcumin: therapeutical potential in ophthalmology","volume":"80","author":"Pescosolido","year":"2014","journal-title":"Planta Med."},{"key":"10.1016\/j.drudis.2019.03.022_bib0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29393-8","article-title":"Topical curcumin nanocarriers are neuroprotective in eye disease","volume":"8","author":"Davis","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.drudis.2019.03.022_bib0155","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ardp.201400266","article-title":"Mitochondria as a target in the therapeutic properties of curcumin","volume":"347","author":"Trujillo","year":"2014","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.drudis.2019.03.022_bib0160","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3233\/JAD-2010-091336","article-title":"PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes","volume":"20","author":"Wang","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.drudis.2019.03.022_bib0165","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.12659\/MSM.895977","article-title":"Combination of aflibercept and bromfenac therapy in age-related macular degeneration: a pilot study aflibercept and bromfenac in AMD","volume":"21","author":"Wygledowska-Promienska","year":"2015","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.drudis.2019.03.022_bib0170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.drudis.2019.03.022_bib0175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000431197","article-title":"Nonsteroidal anti-inflammatory drugs in the treatment of retinal diseases","volume":"55","author":"Rodrigues","year":"2016","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0180","unstructured":"A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration. NCT01089517. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01089517?term5NCT01089517&rank51 [Accessed 20 February 2019]."},{"key":"10.1016\/j.drudis.2019.03.022_bib0185","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3928\/23258160-20170130-02","article-title":"An overview of the fovista and rinucumab trials and the fate of anti-PDGF medications","volume":"48","author":"Dunn","year":"2017","journal-title":"Ophthal. Surg. Lasers Imaging Retin."},{"key":"10.1016\/j.drudis.2019.03.022_bib0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/IAE.0b013e3180323de7","article-title":"Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone","volume":"27","author":"Augustin","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2019.03.022_bib0195","doi-asserted-by":"crossref","first-page":"45506","DOI":"10.18632\/oncotarget.17221","article-title":"Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization","volume":"8","author":"Jo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2019.03.022_bib0200","unstructured":"Zimura in combination with Lucentis in patients with neovascular age related macular degeneration (NVAMD). NCT03362190. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03362190?term5NCT03362190&rank51 [Accessed 20 February 2019]."},{"key":"10.1016\/j.drudis.2019.03.022_bib0205","unstructured":"Comparison of treatment response to intravitreal injection of combined propranolol and bevacizumab versus bevacizumab monotherapy in patients with wet age related macular degeneration: a clinical trial. NCT03609307. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03609307?term5NCT03609307&rank51 [Accessed 20 February 2019]."},{"key":"10.1016\/j.drudis.2019.03.022_bib0210","article-title":"Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants","volume":"2018","author":"Kaempfen","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drudis.2019.03.022_bib0215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clgc.2016.05.010","article-title":"A phase II clinical trial of TRC105 (anti-endoglin antibody) in adults with advanced\/metastatic urothelial carcinoma","volume":"15","author":"Apolo","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.drudis.2019.03.022_bib0220","unstructured":"Study assessing the efficacy and safety of intravitreal injections of DE-122 in combination with Lucentis\u00ae compared to Lucentis\u00ae monotherapy in wet age-related macular degeneration subjects. NCT03211234. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03211234?term5NCT03211234&rank51 [Accessed 20 February 2019]."},{"key":"10.1016\/j.drudis.2019.03.022_bib0225","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008868","article-title":"Concurrent injection of dexamethasone intravitreal implant and anti-angiogenic agent in patients with macular edema: a retrospective cohort study","volume":"96","author":"Lin","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.drudis.2019.03.022_bib0230","first-page":"4","article-title":"Simultaneous therapy with intravitreal dexamethasone implant and bevacizumab for the treatment of macular edema","volume":"5","author":"de Andrade","year":"2016","journal-title":"Med. Hypothesis Discov. Innov. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tjo.2014.03.008","article-title":"Outcomes of combination therapy with dexamethasone implant and bevacizumab in macular edema related to vascular occlusions","volume":"4","author":"Manish Nagpal","year":"2014","journal-title":"Taiwan J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0240","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/eye.2013.79","article-title":"Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion","volume":"27","author":"Mayer","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2019.03.022_bib0245","first-page":"1289","article-title":"Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion","volume":"32","author":"Singer","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2019.03.022_bib0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3341\/kjo.2016.0134","article-title":"Bevacizumab versus dexamethasone implant followed by bevacizumab for the treatment of macula edema associated with branch retinal vein occlusion","volume":"32","author":"Moon","year":"2018","journal-title":"Kor. J. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0255","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/IAE.0000000000001264","article-title":"Role of additional dexamethasone for the management of persistent or recurrent neovascular age-related macular degeneration under ranibizumab treatment","volume":"37","author":"Rezar-Dreindl","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2019.03.022_bib0260","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/phar.1264","article-title":"Age-related macular degeneration","volume":"33","author":"Cheung","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drudis.2019.03.022_bib0265","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1097\/IAE.0000000000000533","volume":"35","author":"Maturi","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2019.03.022_bib0270","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3109\/15569527.2015.1127254","article-title":"Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema","volume":"36","author":"Guler","year":"2017","journal-title":"Cutan. Ocul. Toxicol."},{"issue":"2019","key":"10.1016\/j.drudis.2019.03.022_bib0275","first-page":"98","article-title":"Sequential dexamethasone and aflibercept treatment in patients with diabetic macular edema: structural and functional outcomes at 52 weeks","volume":"241","author":"Hernandez-Bel","year":"2018","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.drudis.2019.03.022_bib0280","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1773-2247(13)50016-5","article-title":"Nano and microtechnologies for ophthalmic administration, an overview","volume":"23","author":"Herrero-Vanrell","year":"2013","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0285","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(01)00200-9","article-title":"Biodegradable microspheres for vitreoretinal drug delivery","volume":"52","author":"Herrero-Vanrell","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2019.03.022_bib0290","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1351\/PAC-REC-10-06-03","article-title":"Terminology of polymers and polymerization processes in dispersed systems","volume":"83","author":"Slomkowski","year":"2011","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.drudis.2019.03.022_bib0295","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.nano.2011.08.018","article-title":"Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs","volume":"8","author":"Holden","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2019.03.022_bib0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.actbio.2018.11.020","article-title":"Bioinspired hydrogels for drug-eluting contact lenses","volume":"84","author":"Alvarez-Lorenzo","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.drudis.2019.03.022_bib0305","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/cxo.12592","article-title":"Contact lenses for ophthalmic drug delivery","volume":"100","author":"Hui","year":"2017","journal-title":"Clin. Exp. Optom."},{"key":"10.1016\/j.drudis.2019.03.022_bib0310","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejpb.2017.10.016","article-title":"Epalrestat-loaded silicone hydrogels as contact lenses to address diabetic-eye complications","volume":"122","author":"Alvarez-Rivera","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.03.022_bib0315","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejpb.2015.06.001","article-title":"Dual drug delivery from vitamin E loaded contact lenses for glaucoma therapy","volume":"94","author":"Hsu","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2019.03.022_bib0320","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ijbiomac.2017.04.117","article-title":"Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: for efficient intra ocular pressure reduction","volume":"104","author":"Natesan","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0325","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2011.06.023","article-title":"Retinal ganglion cells survival in a glaucoma model by GDNF\/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure","volume":"156","author":"Checa-Casalengua","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.03.022_bib0330","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1471-4159.2010.07128.x","article-title":"Glial cell line-derived neurotrophic factor receptor-alpha1 expressed in striatum in trans regulates development and injury response of dopamine neurons of the substantia nigra","volume":"116","author":"Kholodilov","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.drudis.2019.03.022_bib0335","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.survophthal.2008.06.006","article-title":"Potential value of natural antioxidative treatment in glaucoma","volume":"53","author":"Mozaffarieh","year":"2008","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.drudis.2019.03.022_bib0340","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejps.2017.02.037","article-title":"Six month delivery of GDNF from PLGA\/vitamin E biodegradable microspheres after intravitreal injection in rabbits","volume":"103","author":"Garcia-Caballero","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2019.03.022_bib0345","first-page":"733","article-title":"Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF\/melatonin in rhodopsin knockout mice","volume":"24","author":"Garcia-Caballero","year":"2018","journal-title":"Mol. Vis."},{"key":"10.1016\/j.drudis.2019.03.022_bib0350","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2019.01.012","article-title":"Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma","volume":"297","author":"Arranz-Romera","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2019.03.022_bib0355","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2008.297","article-title":"Ophthalmic drug delivery: development and regulatory considerations","volume":"85","author":"Novack","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2019.03.022_bib0360","series-title":"Guideline on Fixed Combination Medicinal Products","author":"EMA","year":"2008"},{"key":"10.1016\/j.drudis.2019.03.022_bib0365","series-title":"Frequently Asked Questions About Combination Products","author":"FDA","year":"2018"},{"key":"10.1016\/j.drudis.2019.03.022_bib0370","series-title":"Combination Products Guidance Documents","author":"FDA","year":"2018"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618303891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618303891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:43:15Z","timestamp":1761223395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618303891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1359644618303891"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.022","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy and co-delivery strategies to optimize treatment of posterior segment neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2019.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}